BEDFORD, Mass.--(BUSINESS WIRE)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that the thirty day review period by the U.S. Food and Drug Administration (FDA) is now complete for an investigational new drug application (IND), with reference #77,896, supporting the use of RX-10045 for the treatment of ophthalmic diseases. The opening of this IND, submitted in early October, allows Resolvyx to initiate its first clinical trial, which will be a placebo-controlled, Phase 1/2 study of RX-10045 in 200 patients with moderate-severe dry eye. The company will initiate this study before the end of the year.
